High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.
Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the recent results “a mixed quarter” and argued that the bar needs to come down before HIMS stock can work again. The ... BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations
June S&P 500 E-Mini futures (ESM26) are up +0.25%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.79% this morning, buoyed by gains in technology stocks, while investors gear up for crucial U.S. producer inflation data and the highly anticipated Trump-Xi summit.
Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after the bell. Here’s what to expect.
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...
Hims & Hers drops after posting unexpected quarterly loss
Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.
HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.
Hims & Hers (NYSE:HIMS) reported first quarter financial results that included a wider-than-expected loss and softer revenue performance, sending shares down nearly 14% to about $25 on Tuesday morning. For the quarter, the telehealth company posted a net loss of $92.1 million, or $0.40...
Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target to $33 from $35 while reaffirming an Overweight rating, characterizing results as mixed and updating the 2026 outlook to reflect the strategic shift ... JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story
The S&P 500 Index ($SPX ) (SPY ) today is down -0.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.45%. June E-mini S&P futures (ESM26 ) are down -0.74%, and June E-mini Nasdaq futures...
Hims & Hers Health reported first-quarter 2026 results with revenue of US$608.1 million, up from US$586.01 million a year earlier, but moved from net income of US$49.49 million to a net loss of US$92.12 million as earnings per share turned from profit to a US$0.40 loss. The company attributed much of the earnings setback to restructuring costs and margin pressure tied to its pivot from compounded to branded GLP-1 weight-loss medications, even as it raised revenue guidance for both the second...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.44%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.72%. June E-mini S&P futures (ESM26 ) are down -0.38%, and June E-mini Nasdaq futures...
Hims & Hers slashed its profitability outlook for 2026. The news sent Hims stock into free fall Tuesday morning.
Shares of Hims & Hers (NYSE:HIMS) dropped roughly 16% in premarket trading on Tuesday after the company reported an unexpected first-quarter loss, missing Wall Street earnings expectations as weaker performance in its U. S.
Revenue outlook rises as Wegovy demand accelerates sharply
Hims & Hers missed on both the top and bottom line
News of the day for May 12, 2026
Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.
Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.
The telehealth company posted a net loss of $92 million in the first quarter as its shift away from compounded weight loss drugs drove up costs
↗️ Venture Global (VG): The liquefied-natural-gas exporter, which stands to benefit from the closure of the Strait of Hormuz, is due to report results this morning, potentially shedding light on the strength of demand.
Despite restructuring costs, Hims & Hers Health Inc (HIMS) reports robust international growth and raises 2026 revenue outlook.
Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call
By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
